AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00586287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm for phenprocoumon
Description: Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
Study NCT00586287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: algorithm for phenprocoumon
Description: Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
Study NCT00586287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
Study NCT00583375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augment® Bone Graft
Description: Augment® Bone Graft
Study NCT00583375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Autologous Bone Graft
Study NCT03152825 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention attempt
Study NCT00924391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytosterol enhanced soy based beverage
Study NCT00924391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1% milk
Study NCT04402281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: suPAR algoritm
Description: All medical patients attending to the ED and who will have blood drawn for routine examination will be part of the study. In patients with low suPAR (green group, suPAR below 3 ng/ml) and in patients with high suPAR (red group, suPAR > 6 ng/mL) the Intervention will be carried out
Study NCT03256292 — intervention group
Intervention type: DRUG
Intervention: Testosterone replacement
Description: Testosterone replacement therapy
Study NCT03256292 — intervention group
Intervention type: BEHAVIORAL
Intervention: lifestyle
Description: lifestyle intervention consisting of diet and increased physical activity
Study NCT00714753 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study NCT00714753 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Study NCT00714753 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided radiation therapy
Study NCT00714753 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study NCT01272141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Everolimus
Description: Lapatinib: 1250 mg by mouth daily~Everolimus: 5mg by mouth daily
Study NCT02253550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.
Study NCT02253550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.
Study NCT04482166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 20-times training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
Study NCT04482166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: supraglottic airway device
Description: supraglottic airway device
Study NCT03393065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid management guided by BLS
Description: We propose a randomized study where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.
Study NCT03229525 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Related Expressive Writing
Description: Participants will write about the traumatic event over the course of six sessions.
Study NCT03229525 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral Expressive Writing
Description: Participants will write about a neutral event over the course of six sessions.
Study NCT03650244 — intervention group
Intervention type: DEVICE
Intervention: REMEEX implantation
Description: Device implantation
Study NCT02672514 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive extracorporeal circulation (MiECC)
Description: Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
Study NCT02672514 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Description: Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
Study NCT00002855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Study NCT00002855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Study NCT00002855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine Phosphate Sodium
Study NCT00002855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Study NCT00002855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Study NCT00002855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilutamide
Study NCT00002855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Study NCT00002855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Study NCT00002855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Surgical castration
Study NCT03747159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab Injection
Description: Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
Study NCT00584376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
Study NCT00584376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
Study NCT03129971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
Study NCT03129971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich plasma
Description: Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
Study NCT02130271 — intervention group
Intervention type: DRUG
Intervention: Radioactive dye
Description: The radioactive dye \[11C\]PBR28 will be administered through an intravenous line (IV).
Study NCT02130271 — intervention group
Intervention type: RADIATION
Intervention: PET/MRI
Description: All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
Study NCT02130271 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
Study NCT05274100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection via prefilled syringe (PFS)
Study NCT05274100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous Infusion
Study NCT05274100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection via on-body delivery system (OBDS)
Study NCT02926495 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: eCoin System
Description: Median nerve neurostimulator.
Study NCT02926495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eCoin System
Description: Median nerve neurostimulator.
Study NCT00938132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimasartan, warfarin
Description: Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
Study NCT02134847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCS intervention schedule
Study NCT01032070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: oral
Study NCT01032070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: oral
Study NCT00609323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and tetracaine cream 7%/7%
Description: One treatment of up to 400 cm2 Cream applied for 60 minutes.
Study NCT03916731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARgraft AV
Description: Implant of STARgraft AV shunt in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
Study NCT03916731 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ePTFE AV graft (control)
Description: Implant of standard ePTFE AV shunt as a control in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
Study NCT00609323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One treatment of up to 400 cm2 Cream applied for 60 minutes.
Study NCT02979613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally once daily
Study NCT03240406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicultural Healthy Diet
Description: An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
Study NCT03240406 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Diet plus Self-Care
Description: Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
Study NCT02861417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo stem cell transplantation
Study NCT02861417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT02861417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02861417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT02861417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02861417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02861417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT02861417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02861417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT02861417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT02783456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Noise
Description: The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.
Study NCT02783456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silence
Description: The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.
Study NCT01734252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Start: Argatroban dose is 0.05 µg/kg/min (patients with hepatic impairment, after cardiac surgery) until maximum: 10 µg/kg/min
Study NCT03863704 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.
Study NCT03863704 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.
Study NCT04022239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo stem cell transplantation
Study NCT04022239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV
Study NCT04022239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04022239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC
Study NCT04022239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04022239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT04022239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT04022239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04022239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT04022239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT04108221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy or laparotomy withTransversusAbdominis Plane Block
Description: The US-TAP is performed by the anesthetist under ultrasound control after the end of the procedure of laparoscopy or laparotomy. Under sterile conditions, the anesthetist identifies the oblique abdominal muscles externally, obliquely internally and transversely by ultrasound. A 20 ml needle of 0.5% ropivacaine is injected.~The surgical TAP (c-TAP) block is performed by the surgeon at the end of the procedure of laparoscopy or laparotomy.The needle and the product used are identical to those of the us-TAP block. The positioning of the needle is in the plane of the fascia between the internal oblique muscle and the transverse muscle, identified by a significant loss of resistance.
Study NCT04108221 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy or laparotomy withTransversusAbdominis Plane Block
Description: The US-TAP is performed by the anesthetist under ultrasound control after the end of the procedure of laparoscopy or laparotomy. Under sterile conditions, the anesthetist identifies the oblique abdominal muscles externally, obliquely internally and transversely by ultrasound. A 20 ml needle of 0.5% ropivacaine is injected.~The surgical TAP (c-TAP) block is performed by the surgeon at the end of the procedure of laparoscopy or laparotomy.The needle and the product used are identical to those of the us-TAP block. The positioning of the needle is in the plane of the fascia between the internal oblique muscle and the transverse muscle, identified by a significant loss of resistance.
Study NCT04489875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Description: The intervention would be chewing gum. The patients in the intervention arm would be asked to chew gum for 15 minutes before meals thrice a day.
Study NCT00524004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CsbD Bovine IgG
Description: Three times a day for seven days
Study NCT00524004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Three times a day for seven days
Study NCT00524004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CS17 Bovin IgG
Description: Three times a day for seven days
Study NCT04306887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3101 capsule
Description: Escalating doses starting at 200 mg bid.
Study NCT03157739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MigraineManager: Individualized Self-Management Tool
Description: Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
Study NCT02604550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
Study NCT02604550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet 7.5/325
Description: Percocet 7.5/325 will taken as needed up to every four hours.
Study NCT02604550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn 500 mg
Description: Naprosyn 500 mg will be taken twice daily.
Study NCT03035435 — intervention group
Intervention type: OTHER
Intervention: fast-track rehabilitation
Study NCT03035435 — intervention group
Intervention type: OTHER
Intervention: standard care rehabilitation
Study NCT02568618 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Pain Medication DNA Insight (TM) test
Description: The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.
Study NCT02956057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycols
Study NCT02956057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrium picosulfate / Magnesium citrate
Study NCT02956057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol / Ascorbic acid
Study NCT03229629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change communication
Description: Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks
Study NCT03229629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Voucher (Monetary)
Description: Monthly voucher worth 200 birr(\~$10) every month for the duration of 6 month
Study NCT04518969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Description: CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist.
Study NCT04205344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 mg
Description: Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
Study NCT04205344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 10 mg
Description: Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
Study NCT02979613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF
Description: 25 mg tablet administered orally once daily
Study NCT02979613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily
Study NCT02979613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF Placebo
Description: Tablet administered orally once daily
Study NCT02979613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF Placebo
Description: Tablet administered orally once daily
Study NCT00057044 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: education and reminder
Study NCT01079754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal morphine 0.05 mg
Description: Patient received spinal morphine 0.05 mg
Study NCT01079754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal morphine 0.1 mg
Description: Patient received spinal morphine 0.1 mg
Study NCT00699231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: IM injection
Study NCT00699231 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: IM injection
Study NCT00631085 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: gamma tocopherol
Description: Maxi Gamma softgels 1200mg QD